Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma - PubMed (original) (raw)
Meta-Analysis
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al. J Clin Oncol. 2015.
Abstract
Purpose: To provide a more precise estimate of long-term survival observed for ipilimumab-treated patients with advanced melanoma, we performed a pooled analysis of overall survival (OS) data from multiple studies.
Methods: The primary analysis pooled OS data for 1,861 patients from 10 prospective and two retrospective studies of ipilimumab, including two phase III trials. Patients were previously treated (n = 1,257) or treatment naive (n = 604), and the majority of patients received ipilimumab 3 mg/kg (n = 965) or 10 mg/kg (n = 706). We also conducted a secondary analysis of OS data (n = 4,846) with an additional 2,985 patients from an expanded access program. OS rates were estimated using the Kaplan-Meier method.
Results: Among 1,861 patients, median OS was 11.4 months (95% CI, 10.7 to 12.1 months), which included 254 patients with at least 3 years of survival follow-up. The survival curve began to plateau around year 3, with follow-up of up to 10 years. Three-year survival rates were 22%, 26%, and 20% for all patients, treatment-naive patients, and previously treated patients, respectively. Including data from the expanded access program, median OS was 9.5 months (95% CI, 9.0 to 10.0 months), with a plateau at 21% in the survival curve beginning around year 3.
Conclusion: To our knowledge, this is the largest analysis of OS to date for ipilimumab-treated patients with advanced melanoma. We observed a plateau in the survival curve, beginning at approximately 3 years, which was independent of prior therapy or ipilimumab dose. These data add to the evidence supporting the durability of long-term survival in ipilimumab-treated patients with advanced melanoma.
Trial registration: ClinicalTrials.gov NCT00032045 NCT00058279 NCT00077532 NCT00094653 NCT00135408 NCT00261365 NCT00289627 NCT00289640 NCT00324155 NCT00623766.
© 2015 by American Society of Clinical Oncology.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Figures
Fig 1.
Primary analysis of pooled overall survival (OS) data. Individual patient data were pooled from 10 prospective trials and two retrospective, observational studies of ipilimumab in metastatic melanoma (n = 1,861). Median OS was 11.4 months (95% CI, 10.7 to 12.1 months) with a 3-year survival rate of 22% (95% CI, 20% to 24%). Crosses indicate censored patients.
Fig 2.
Subset analysis of overall survival (OS) by prior therapy. Nonrandomized subset analysis of OS in treatment-naive (n = 604) and previously treated (n = 1,257) patients with metastatic melanoma who received ipilimumab in 10 prospective trials and two retrospective, observational studies. Median OS was 13.5 months (95% CI, 11.9 to 15.4 months) for treatment-naive patients and 10.7 months (95% CI, 9.6 to 11.4 months) for previously treated patients, with 3-year survival rates of 26% (95% CI, 21% to 30%) and 20% (95% CI, 18% to 23%), respectively. Crosses indicate censored patients.
Fig 3.
Subset analysis of overall survival (OS) by ipilimumab dose. Nonrandomized subset analysis of OS in patients who received ipilimumab at 3 mg/kg (n = 965), 10 mg/kg (n = 706), or other dosing regimens (n = 190) in 10 prospective trials and two retrospective, observational studies. Median OS was 11.4 months (95% CI, 10.3 to 12.5 months) for 3 mg/kg, 11.1 months (95% CI, 9.9 to 13.0 months) for 10 mg/kg, and 12.4 months (95% CI, 10.4 to 15.1 months) for other dosing regimens; the 3-year survival rates were 21% (95% CI, 17% to 24%), 24% (95% CI, 21% to 28%), and 20% (95% CI, 14% to 26%), respectively. Crosses indicate censored patients.
Fig 4.
Pooled overall survival (OS) analysis with expanded access protocol (EAP) data. Individual patient survival data were pooled from 1,861 patients with metastatic melanoma from 12 clinical investigations of ipilimumab and 2,985 patients with metastatic melanoma from a US EAP (n = 4,846). Median OS was 9.5 months (95% CI, 9.0 to 10.0 months) with a 3-year survival rate of 21% (95% CI, 20% to 22%). Crosses indicate censored patients.
Comment in
- Gauging the Long-Term Benefits of Ipilimumab in Melanoma.
Ribas A, Flaherty KT. Ribas A, et al. J Clin Oncol. 2015 Jun 10;33(17):1865-6. doi: 10.1200/JCO.2014.59.5041. Epub 2015 Feb 9. J Clin Oncol. 2015. PMID: 25667273 No abstract available.
Similar articles
- Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, Garbe C, Herbst R, Enk A, Kämpgen E, Livingstone E, Bluhm L, Rompel R, Griewank KG, Fluck M, Schilling B, Schadendorf D. Zimmer L, et al. PLoS One. 2015 Mar 11;10(3):e0118564. doi: 10.1371/journal.pone.0118564. eCollection 2015. PLoS One. 2015. PMID: 25761109 Free PMC article. Clinical Trial. - Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.
Thompson JA, Hamid O, Minor D, Amin A, Ron IG, Ridolfi R, Assi H, Berman D, Siegel J, Weber JS. Thompson JA, et al. J Immunother. 2012 Jan;35(1):73-7. doi: 10.1097/CJI.0b013e31823735d6. J Immunother. 2012. PMID: 22130164 Clinical Trial. - Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
Zimmer L, Eigentler TK, Kiecker F, Simon J, Utikal J, Mohr P, Berking C, Kämpgen E, Dippel E, Stadler R, Hauschild A, Fluck M, Terheyden P, Rompel R, Loquai C, Assi Z, Garbe C, Schadendorf D. Zimmer L, et al. J Transl Med. 2015 Nov 6;13:351. doi: 10.1186/s12967-015-0716-5. J Transl Med. 2015. PMID: 26541511 Free PMC article. Clinical Trial. - Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G, Tentori L, Navarra P. Graziani G, et al. Pharmacol Res. 2012 Jan;65(1):9-22. doi: 10.1016/j.phrs.2011.09.002. Epub 2011 Sep 10. Pharmacol Res. 2012. PMID: 21930211 Review. - Ipilimumab: a novel treatment for metastatic melanoma.
Culver ME, Gatesman ML, Mancl EE, Lowe DK. Culver ME, et al. Ann Pharmacother. 2011 Apr;45(4):510-9. doi: 10.1345/aph.1P651. Epub 2011 Apr 19. Ann Pharmacother. 2011. PMID: 21505108 Review.
Cited by
- Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality?
Brugiapaglia S, Spagnolo F, Intonti S, Novelli F, Curcio C. Brugiapaglia S, et al. Cells. 2024 Sep 16;13(18):1558. doi: 10.3390/cells13181558. Cells. 2024. PMID: 39329742 Free PMC article. Review. - Recent development of nanomaterials-based PDT to improve immunogenic cell death.
Ain QT. Ain QT. Photochem Photobiol Sci. 2024 Sep 25. doi: 10.1007/s43630-024-00638-y. Online ahead of print. Photochem Photobiol Sci. 2024. PMID: 39320675 Review. - The interaction of innate immune and adaptive immune system.
Wang R, Lan C, Benlagha K, Camara NOS, Miller H, Kubo M, Heegaard S, Lee P, Yang L, Forsman H, Li X, Zhai Z, Liu C. Wang R, et al. MedComm (2020). 2024 Sep 15;5(10):e714. doi: 10.1002/mco2.714. eCollection 2024 Oct. MedComm (2020). 2024. PMID: 39286776 Free PMC article. Review. - Toxicity in the era of immune checkpoint inhibitor therapy.
Keam S, Turner N, Kugeratski FG, Rico R, Colunga-Minutti J, Poojary R, Alekseev S, Patel AB, Li YJ, Sheshadri A, Loghin ME, Woodman K, Aaroe AE, Hamidi S, Iyer PC, Palaskas NL, Wang Y, Nurieva R. Keam S, et al. Front Immunol. 2024 Aug 23;15:1447021. doi: 10.3389/fimmu.2024.1447021. eCollection 2024. Front Immunol. 2024. PMID: 39247203 Free PMC article. Review. - Locoregional therapies combined with immune checkpoint inhibitors for liver metastases.
Zhang XC, Zhou YW, Wei GX, Luo YQ, Qiu M. Zhang XC, et al. Cancer Cell Int. 2024 Aug 31;24(1):302. doi: 10.1186/s12935-024-03484-1. Cancer Cell Int. 2024. PMID: 39217341 Free PMC article. Review.
References
- Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy with metastatic melanoma: Long-term survival update. Cancer J Sci Am. 2000;6(suppl 1):S11–S14. - PubMed
- Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7:95–106. - PubMed
- Hoos A, Ibrahim R, Korman A, et al. Development of ipilimumab: Contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010;37:533–546. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical